Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06318663 · ClinicalTrials.gov registry record · NA
Survivor Mom Companion Comparison Study
A NA study, sponsored by State University of New York at Buffalo.
- Completed
- Registry status
- NA
- Development phase
- 39
- Enrollment target
NCT06318663: Completed NA study, sponsored by State University of New York at Buffalo.
NCT06318663 is a NA study that has completed, run by State University of New York at Buffalo. The registered enrollment target is 39 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06318663, a NA study, has completed, sponsored by State University of New York at Buffalo.
- COMPLETED
- Registry status
- NA
- Development phase
- 39 participants
- Enrollment target
Study Summary
The overall goal of the SMC is to help reduce posttraumatic stress symptomology for pregnant persons with a history of trauma.
Primary Outcome
For eligibility screening we will use the 5 sentinel items from the Childhood Trauma Questionnaire. The higher the score is, the greater the severity of abuse for that scale. There are four categories of severity for each trauma type: None (minimal); Low (to Moderate); Moderate (to Severe); and Severe (to Extreme).
Interventions
- OTHER Survivor Mom Companion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2023-12-12 |
| Est. Completion | 2024-11-11 |
| Phase | NA |
What the finished NCT06318663 record still lists
NCT06318663 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which Survivor Mom Companion is the first listed.
NCT06318663 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06318663 about?
NCT06318663 is a clinical study titled "Survivor Mom Companion Comparison Study". The overall goal of the SMC is to help reduce posttraumatic stress symptomology for pregnant persons with a history of trauma.
What is the current status of trial NCT06318663?
This trial is currently completed. It is a NA study. The enrollment target is 39 participants. The study started on 2023-12-12. Estimated completion is 2024-11-11.
What interventions are being tested in trial NCT06318663?
The interventions under investigation include: Survivor Mom Companion (OTHER).
Who is sponsoring clinical trial NCT06318663?
This trial is sponsored by State University of New York at Buffalo, which has 243 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06318663's enrollment target sits among peer trials
39 1536th of 2000 higher than 463 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI